RIPK3 and cancer: To compensate for this severe disparity, over the years, researchers have relied on proxy approaches such as exploiting the genetic expression of pro-necroptotic molecules (especially RIPK3 or MLKL genes) as well as their univariate or multivariate impacts on human cancer patient’s survival or anticancer therapy responsiveness to study their correlations with inflammatory or immunological parameters.